Contact
searchSearch
HMP Global
Login

Bladder Cancer Specialty Channel

Bladder Cancer
Specialty Channel
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Extended Lymphadenectomy Fails to Improve Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer
11/05/2024
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.
Results from the phase 2 SWOG...
11/05/2024
Oncology
News
Adjuvant Pembrolizumab for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma
10/24/2024
According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.
According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.
According to the phase 3...
10/24/2024
Oncology
News
Perioperative Durvalumab Improved Survival Outcomes for Patients With Operable, Muscle-Invasive Bladder Cancer
10/24/2024
According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive...
According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive...
According to the phase 3 NIAGARA...
10/24/2024
Oncology
News
Optimal Rogaratinib Dose for Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Advanced Urothelial Cancer
10/23/2024
According to results from the phase 1b FORT-2 study, 600 mg of rogaratinib is preferable to 800 mg among cisplatin-ineligible patients with FGFR RNA-overexpressing locally advanced or metastatic urothelial cancer being treated with...
According to results from the phase 1b FORT-2 study, 600 mg of rogaratinib is preferable to 800 mg among cisplatin-ineligible patients with FGFR RNA-overexpressing locally advanced or metastatic urothelial cancer being treated with...
According to results from the...
10/23/2024
Oncology
Andrea Necchi, MD
Conference Coverage
TAR-200 Plus Cetrelimab Provides Promising Clinical Benefit for Patients With Muscle-Invasive Bladder Cancer
10/23/2024
Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...
Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...
Andrea Necchi, MD, discusses...
10/23/2024
Oncology
Conference Coverage
Durvalumab Added to Neoadjuvant Chemotherapy Improves Survival Outcomes in Muscle-Invasive Bladder Cancer: NIAGARA Trial
09/15/2024
The NIAGARA trial showed that durvalumab plus neoadjuvant chemotherapy improved EFS and OS compared to neoadjuvant chemotherapy alone in patients with muscle-invasive bladder cancer.
The NIAGARA trial showed that durvalumab plus neoadjuvant chemotherapy improved EFS and OS compared to neoadjuvant chemotherapy alone in patients with muscle-invasive bladder cancer.
The NIAGARA trial showed that...
09/15/2024
Oncology
News
Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer
09/10/2024
According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...
According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...
According to results from Cohort...
09/10/2024
Oncology
News
Pembrolizumab Monotherapy Shows Promise Among Patients With BCG-Unresponsive, High-Risk NMIBC With Papillary Tumors, Without Carcinoma in Situ
05/22/2024

Stephanie Holland 

Stephanie Holland 
According to results from cohort B of the phase 2 KEYNOTE-057 trial, pembrolizumab monotherapy demonstrated promising activity with manageable toxicity among patients with Bacillus Calmette-Guerin–unresponsive, high-risk non-muscle invasive...
According to results from cohort B of the phase 2 KEYNOTE-057 trial, pembrolizumab monotherapy demonstrated promising activity with manageable toxicity among patients with Bacillus Calmette-Guerin–unresponsive, high-risk non-muscle invasive...
According to results from cohort...
05/22/2024
Oncology
FDA Approval
FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer
04/23/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase...
04/23/2024
Oncology
Andrew Katims, MD, MPH
Videos
Navigating the Bacillus Calmette-Guerin Shortage for Patients With High-Risk Non-Muscle Invasive Bladder Cancer
04/08/2024

Featuring Andrew Katims, MD, MPH

Featuring Andrew Katims, MD, MPH ...
Andrew Katims, MD, discusses the challenges of treating patients with high-risk non-muscle invasive bladder cancer during the bacillus Calmette-Guerin shortage.
Andrew Katims, MD, discusses the challenges of treating patients with high-risk non-muscle invasive bladder cancer during the bacillus Calmette-Guerin shortage.
Andrew Katims, MD, discusses the...
04/08/2024
Oncology

News

News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Extended Lymphadenectomy Fails to Improve Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer
11/05/2024
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.
Results from the phase 2 SWOG...
11/05/2024
Oncology
News
Adjuvant Pembrolizumab for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma
10/24/2024
According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.
According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.
According to the phase 3...
10/24/2024
Oncology
News
Perioperative Durvalumab Improved Survival Outcomes for Patients With Operable, Muscle-Invasive Bladder Cancer
10/24/2024
According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive...
According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive...
According to the phase 3 NIAGARA...
10/24/2024
Oncology
News
Optimal Rogaratinib Dose for Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Advanced Urothelial Cancer
10/23/2024
According to results from the phase 1b FORT-2 study, 600 mg of rogaratinib is preferable to 800 mg among cisplatin-ineligible patients with FGFR RNA-overexpressing locally advanced or metastatic urothelial cancer being treated with...
According to results from the phase 1b FORT-2 study, 600 mg of rogaratinib is preferable to 800 mg among cisplatin-ineligible patients with FGFR RNA-overexpressing locally advanced or metastatic urothelial cancer being treated with...
According to results from the...
10/23/2024
Oncology
Andrea Necchi, MD
Conference Coverage
TAR-200 Plus Cetrelimab Provides Promising Clinical Benefit for Patients With Muscle-Invasive Bladder Cancer
10/23/2024
Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...
Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...
Andrea Necchi, MD, discusses...
10/23/2024
Oncology
Conference Coverage
Durvalumab Added to Neoadjuvant Chemotherapy Improves Survival Outcomes in Muscle-Invasive Bladder Cancer: NIAGARA Trial
09/15/2024
The NIAGARA trial showed that durvalumab plus neoadjuvant chemotherapy improved EFS and OS compared to neoadjuvant chemotherapy alone in patients with muscle-invasive bladder cancer.
The NIAGARA trial showed that durvalumab plus neoadjuvant chemotherapy improved EFS and OS compared to neoadjuvant chemotherapy alone in patients with muscle-invasive bladder cancer.
The NIAGARA trial showed that...
09/15/2024
Oncology
News
Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer
09/10/2024
According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...
According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...
According to results from Cohort...
09/10/2024
Oncology
News
Pembrolizumab Monotherapy Shows Promise Among Patients With BCG-Unresponsive, High-Risk NMIBC With Papillary Tumors, Without Carcinoma in Situ
05/22/2024

Stephanie Holland 

Stephanie Holland 
According to results from cohort B of the phase 2 KEYNOTE-057 trial, pembrolizumab monotherapy demonstrated promising activity with manageable toxicity among patients with Bacillus Calmette-Guerin–unresponsive, high-risk non-muscle invasive...
According to results from cohort B of the phase 2 KEYNOTE-057 trial, pembrolizumab monotherapy demonstrated promising activity with manageable toxicity among patients with Bacillus Calmette-Guerin–unresponsive, high-risk non-muscle invasive...
According to results from cohort...
05/22/2024
Oncology
FDA Approval
FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer
04/23/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase...
04/23/2024
Oncology

Interactive Features

Quiz
Enfortumab Vedotin for Patients With Advanced Urothelial Carcinoma
10/19/2023
True or False: According to findings from the phase 3 EV-301 trial, enfortumab vedotin maintained clinically meaningful overall survival benefit at a median follow-up of approximately 2 years, compared with chemotherapy, among patients with...
True or False: According to findings from the phase 3 EV-301 trial, enfortumab vedotin maintained clinically meaningful overall survival benefit at a median follow-up of approximately 2 years, compared with chemotherapy, among patients with...
True or False: According to...
10/19/2023
Oncology
Quiz
NECTIN-4 Expression During Metastatic Spread in Urothelial Carcinoma
02/10/2023
In a study evaluating the changes in membranous NECTIN-4 protein expression among urothelial carcinoma progression, what percentage of cases demonstrated a decrease of NECTIN-4 expression during metastatic spread?
In a study evaluating the changes in membranous NECTIN-4 protein expression among urothelial carcinoma progression, what percentage of cases demonstrated a decrease of NECTIN-4 expression during metastatic spread?
In a study evaluating the...
02/10/2023
Oncology
Quiz
Quiz: Rogaratinib Compared With Standard Chemotherapy for FGFR-Altered Urothelial Carcinoma
12/01/2022
In the open-label, multicenter FORT-1 trial, how did the pan-FGFR inhibitor rogaratinib compare to standard chemotherapy, in terms of efficacy in treating patients with FGFR-altered urothelial carcinoma?
In the open-label, multicenter FORT-1 trial, how did the pan-FGFR inhibitor rogaratinib compare to standard chemotherapy, in terms of efficacy in treating patients with FGFR-altered urothelial carcinoma?
In the open-label, multicenter...
12/01/2022
Oncology
Quiz
Quiz: Following TURBT, which treatment was found to be a safe, effective alternative to BCG for patients with NMIBC?
10/18/2022
Following transurethral resection of bladder tumor, which treatment was found to be an effective and safe alternative to bacillus Calmete-Guérin for patients with non-muscle invasive bladder cancer?
Following transurethral resection of bladder tumor, which treatment was found to be an effective and safe alternative to bacillus Calmete-Guérin for patients with non-muscle invasive bladder cancer?
Following transurethral...
10/18/2022
Oncology
Quiz
Quiz: Radical Cystectomy vs Intravesical Therapy for Non-Muscle Invasive Bladder Cancer
09/02/2022
What was the difference in survival found between patients with non-muscle invasive bladder cancer who underwent radical cystectomy vs those who underwent intravesical therapy, within 12 months of receiving BCG?
What was the difference in survival found between patients with non-muscle invasive bladder cancer who underwent radical cystectomy vs those who underwent intravesical therapy, within 12 months of receiving BCG?
What was the difference in...
09/02/2022
Oncology
Test Your Knowledge
Quiz: Which Phase 2 Trial Led to the Approval of Sacituzumab Govitecan for aUC?
02/20/2022
The approval of sacituzumab govitecan  for patients with advanced urothelial cancer was based on which phase 2 trial?
The approval of sacituzumab govitecan  for patients with advanced urothelial cancer was based on which phase 2 trial?
The approval of sacituzumab...
02/20/2022
Oncology
Quiz
Quiz: Which Immunotherapy Drug Treats Advanced or Metastatic Urothelial Cancer?
07/01/2021
Which immunotherapy drug was recently granted accelerated approval by the FDA to treat adult patients with locally advanced or metastatic urothelial cancer?
Which immunotherapy drug was recently granted accelerated approval by the FDA to treat adult patients with locally advanced or metastatic urothelial cancer?
Which immunotherapy drug was...
07/01/2021
Oncology
Quiz
Quiz: Does Nivolumab Provide the Longest DFS Rate for Urothelial Carcinoma?
07/01/2021
In a recent trial that evaluated various treatments for patients with high-risk muscle-invasive urothelial carcinoma, adjuvant nivolumab provided the longest disease-free survival rate.
In a recent trial that evaluated various treatments for patients with high-risk muscle-invasive urothelial carcinoma, adjuvant nivolumab provided the longest disease-free survival rate.
In a recent trial that evaluated...
07/01/2021
Oncology
Test Your Knowledge
Quiz: Risk of Recurrence and Progression for Patients with NMIBC
02/19/2021
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does...
02/19/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment Received FDA Approval for Metastatic Urothelial Carcinoma?
11/03/2020
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by...
11/03/2020
Oncology

Recent News

News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Extended Lymphadenectomy Fails to Improve Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer
11/05/2024
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.
Results from the phase 2 SWOG...
11/05/2024
Oncology
News
Adjuvant Pembrolizumab for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma
10/24/2024
According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.
According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.
According to the phase 3...
10/24/2024
Oncology
News
Perioperative Durvalumab Improved Survival Outcomes for Patients With Operable, Muscle-Invasive Bladder Cancer
10/24/2024
According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive...
According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive...
According to the phase 3 NIAGARA...
10/24/2024
Oncology
News
Optimal Rogaratinib Dose for Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Advanced Urothelial Cancer
10/23/2024
According to results from the phase 1b FORT-2 study, 600 mg of rogaratinib is preferable to 800 mg among cisplatin-ineligible patients with FGFR RNA-overexpressing locally advanced or metastatic urothelial cancer being treated with...
According to results from the phase 1b FORT-2 study, 600 mg of rogaratinib is preferable to 800 mg among cisplatin-ineligible patients with FGFR RNA-overexpressing locally advanced or metastatic urothelial cancer being treated with...
According to results from the...
10/23/2024
Oncology
News
Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer
09/10/2024
According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...
According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...
According to results from Cohort...
09/10/2024
Oncology
News
Pembrolizumab Monotherapy Shows Promise Among Patients With BCG-Unresponsive, High-Risk NMIBC With Papillary Tumors, Without Carcinoma in Situ
05/22/2024

Stephanie Holland 

Stephanie Holland 
According to results from cohort B of the phase 2 KEYNOTE-057 trial, pembrolizumab monotherapy demonstrated promising activity with manageable toxicity among patients with Bacillus Calmette-Guerin–unresponsive, high-risk non-muscle invasive...
According to results from cohort B of the phase 2 KEYNOTE-057 trial, pembrolizumab monotherapy demonstrated promising activity with manageable toxicity among patients with Bacillus Calmette-Guerin–unresponsive, high-risk non-muscle invasive...
According to results from cohort...
05/22/2024
Oncology
FDA Approval
FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer
04/23/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase...
04/23/2024
Oncology
News
FDA Grants Approval for Nivolumab Plus Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma in First-Line Setting
03/08/2024

Allison Casey

Allison Casey
On March 7, 2024, the FDA approved nivolumab plus gemcitabine and cisplatin for patients with unresectable or metastatic urothelial carcinoma in the first-line setting.
On March 7, 2024, the FDA approved nivolumab plus gemcitabine and cisplatin for patients with unresectable or metastatic urothelial carcinoma in the first-line setting.
On March 7, 2024, the FDA...
03/08/2024
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
News
Enfortumab Vedotin Plus Pembrolizumab Beats Chemotherapy for Survival Outcomes Among Patients With Untreated Advanced Urothelial Carcinoma
03/07/2024
According to a phase 3 study, enfortumab vedotin plus pembrolizumab significantly improved progression-free survival and overall survival compared to chemotherapy among patients with untreated advanced urothelial carcinoma.
According to a phase 3 study, enfortumab vedotin plus pembrolizumab significantly improved progression-free survival and overall survival compared to chemotherapy among patients with untreated advanced urothelial carcinoma.
According to a phase 3 study,...
03/07/2024
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use